EuroPCR 2024 | Specific Intracoronary Tests Combined with Angiography for Diagnosing Patients with Chronic Coronary Syndrome: The AID-ANGIO Study

Invasive coronary angiography (ICA) has become the gold standard for the assessment of patients with chronic coronary syndrome (CCS) for obstructive coronary artery disease. However, its ability to detect this condition is limited and it does not detect non-obstructive myocardial ischemia, which can be overlooked.

EuroPCR 2024

To address these limitations, a prospective, observational, multicenter study was conducted to assess the diagnostic performance of advanced invasive diagnosis (AID), which included measuring coronary flow reserve (CFR) and microvascular resistance, and the acetylcholine test, to identify both obstructive and non-obstructive causes of myocardial ischemia in patients with CCS.

The primary endpoint (PEP) of the study was to determine the proportion of patients whose cause of myocardial ischemia was identified using ICA alone compared with ICA + AID.

As a secondary endpoint (SEP), the study assessed the proportion of patients in whom ischemia and non-obstructive coronary artery disease (INOCA) was identified, and the proportion of cases in which AID facilitated the modification of the initial therapeutic plan.

Read also: EuroPCR 2024 | Influence and Effect of CAD Physiopathological Patterns in the Safety and Efficacy of PCI.

The study included 317 patients; most of them were men with an average age of 66 years. Most experienced angina symptoms and around 60% had positive non-invasive ischemia tests. There were complications in a low percentage of cases, mainly related to iatrogenic dissection (0.6%) and ventricular arrhythmias (0.3%), with no events of death or myocardial infarction.

Results showed that ICA alone identified the cause of ischemia in only 32% of patients, while AID identified it in 84% of cases, a significant increase in diagnostic performance compared to ICA alone (p <0.001). Additionally, AID identified a 45-% prevalence of INOCA, and only 16% of all patients undergoing ICA showed no abnormalities. AID also resulted in a change in the initial therapeutic plan in nearly 60% of cases.

Conclusion

In conclusion, AID proved to be a safe and effective strategy for the identification of the causes of myocardial ischemia in more than 80% of patients with CCS, leading to changes in the initial therapeutic plan in most cases.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Combining angiography and pre-specified intracoronary testing in patients with chronic coronary syndromes: the AID-ANGIO study.

Reference: Adrian Jeronimo et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity, calcification, raphe presence, aortic dilation and associated...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...